

2017 Glaucoma Pharmaceuticals Report

A Global Market Analysis for 2016 to 2022



What's New

AUTHOR
Peter Downs

RELEASED
August 2017

The outlook for the glaucoma pharmaceuticals market is growing more positive as new products with new mechanisms of action begin commercialization or enter the final stages of the regulatory approval process. Market Scope estimates the glaucoma pharmaceuticals market will reach \$5.3 billion in 2022. However, prospects vary considerably by region.

Market Scope

2017 Glaucoma Pharmaceuticals Report

Market Scope's 2017 Glaucoma Pharmaceuticals Report provides in-depth coverage of commercialized and investigational glaucoma medications in the market.

Four Disease Categories Are Analyzed In This Report:


Primary Open-angle Glaucoma (POAG), Primary Angle-closure Glaucoma (PACG), Other Secondary OAG and ACG, and Ocular Hypertension (OHT)

Each Market Segment Includes:

An Analysis of Market Competitors and Five-Year Forecasts for Market Performance

Also Included in This Report:

- Overview of Glaucoma
- Prevalence of Glaucoma and Diagnosed Cases
- Glaucoma Care Providers
- Diagnosing Glaucoma
- Treating Glaucoma
- Glaucoma Medications in the Marketplace
- Development Pipeline for Glaucoma Rx
- Adjunctive Drugs Used in Glaucoma Surgery
- 26 Company Profiles
- 54 Color Tables and 36 Color Figures



Our report on the glaucoma pharmaceuticals market, now in its fourth edition, is a leading industry source for accurate and relevant information on all aspects of the glaucoma pharmaceuticals market. The glaucoma pharmaceuticals market is one of the largest and most complex market segments in ophthalmology with a variety of drug classes, as well as proprietary and generic versions of many drugs. Current ocular hypotensive medication classes used to treat glaucoma were developed 20 years ago or more, and generic versions of these medications are now in widespread use.

> This report includes market data for 2016, and we forecast market performance through 2022.

How to Order

Order your 2017 Glaucoma Pharmaceuticals Report now at www.market-scope.com or contact us directly via email or phone.



ENTERPRISE LICENSE

2017 Glaucoma
Pharmaceuticals Report
\$9,750

(Price includes a printable PDF and supplemental Excel file with all the tables and figures in the report)



SINGLE-USER LICENSE

2017 Glaucoma
Pharmaceuticals Report
\$6,500

+ Additional Printable Electronic PDF **\$500**
+ Additional Paper Copy **\$300**



ONE-YEAR SUBSCRIPTION

Ophthalmic Market
Perspectives Newsletter
\$900

(Outside the US — \$950)

314.835.0600 | info@market-scope.com

Please add \$50 for shipping if ordering from outside the US.

Our Process

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective ophthalmic experience and each data point is driven by a combination of sources, including the following:

- Our proprietary global disease population and demographic models
- Twenty years and counting of ophthalmologist survey data
- Analysis of company published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in major, worldwide ophthalmic meetings
- Interviews and long-standing relationships with company executives and practicing ophthalmologists



About Us

Market Scope is recognized as the leading source for accurate and timely industry information in ophthalmology.

We have been conducting primary research and producing comprehensive reports on ophthalmic markets since 1996. Our data, analysis, and forecasts serve as starting points for many annual planning cycles, strategic plans, acquisition analyses, and return-on-investment decisions in the industry. In addition, our information is routinely included in annual reports, SEC filings, and investor presentations by leading ophthalmic companies.

TABLE OF CONTENTS

INTRODUCTION

Scope of Report
Methodology
About the Author
The Report at a Glance

EXECUTIVE SUMMARY

Glaucoma and its Prevalence
The Global Market
Current Market Competitors
Factors Shaping the Marketplace

ABOUT GLAUCOMA

Open-Angle Glaucoma (OAG)
Normal-Tension Glaucoma as a Subset of OAG
Exfoliation Glaucoma (XFG) as a Subset of OAG
Angle-Closure Glaucoma (ACG)
Risk Factors for Primary Glaucomas
Secondary Glaucomas
Pigmentary Glaucoma
Neovascular Glaucoma
Uveitic Glaucoma
Trauma-Related Glaucoma
Steroid-Induced Glaucoma
Lens-Induced Glaucoma
Iridocorneal Endothelial Syndrome
Congenital Glaucoma
Ocular Hypertension (OHT)
Genetics of Glaucoma

PREVALENCE OF GLAUCOMA

Overview of Glaucoma Prevalence Research
Global Prevalence by Disease Type
Factors Shaping Worldwide Distribution of Glaucoma
Diagnosed POAG
Diagnosed PACG
United States
Western Europe
Japan
Other Wealthy Nations
China
India
Latin America
Rest of World
Growth in Glaucoma Populations

GLAUCOMA CARE PROVIDERS

Overview of Providers, Diagnosis, Treatment
Care Providers and Diagnostic Facilities
US Providers
US Ophthalmologists and Glaucoma Specialists
Profile of the US Ophthalmologist
Profile of the US Optometrist
Western Europe's Providers
Ophthalmology and Health Care Systems
Optometry
Japan's Providers
Ophthalmology and the Health Care System
Optometry
Other Wealthy Nations' Providers
Ophthalmology and Health Care Systems

Optometry
China's Providers
Ophthalmology and the Health Care System
Optometry
India's Providers
Ophthalmology and the Health Care System
Optometry
Latin America's Providers
Ophthalmology and Health Care Systems
Optometry
Select Country Snapshots
Rest of World's Providers
Ophthalmologist and Health Care Systems
Optometry
Glaucoma Organizations and Foundations

DIAGNOSING GLAUCOMA

Tonometry
Pachymetry
Perimetry or Visual Field Testing
Ophthalmoscopy
Fundus Photography
Optical Coherence Tomography
Confocal Scanning Laser Ophthalmoscopy
Scanning Laser Polarimetry
Glaucoma Scope Examination
Slit Lamp Biomicroscopy
Gonioscopy with Contact Lens
Ultrasound Biomicroscopy
Diagnosed Disease Rates
Growth in Glaucoma's Diagnosis

TREATING GLAUCOMA

Treatment Modalities
Rx Medications
Treating Open-Angle Glaucoma
Treating IOP in Ocular Hypertension Patients
Treating Exfoliation/Pseudoexfoliation
Glaucoma (XFG/PEG)
Treating Angle-Closure Glaucoma
Limitations of Current Medications
Referral to Glaucoma Specialists
Laser and Surgery
Laser Procedures
Traditional Surgical Treatment
Newer Surgical Approaches
Traditional Medicine and Alternative Therapies
China
India
Other Alternative Medicine
Marijuana

THE CHALLENGES OF MANAGING GLAUCOMA

The Key Role of IOP
A Competing Theory Regarding IOP and Glaucoma
Growing Glaucoma Treatment Options
How Ophthalmologists Determine the Best
POAG Treatment Option
POAG Stages and Typical Treatment Approaches

GLAUCOMA MEDICATIONS IN THE MARKETPLACE

Rho Kinase Inhibitor
Prostaglandin Analogs and Prostaglandin Synthase Inhibitors
Beta Blockers
Alpha Agonists
Selective Alpha Adrenergic Agonists
Nonselective Alpha Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Cholinergic Agonists
Fixed Combination Medications
Comparative IOP Reduction: Brands and MOAs
The Market Mix: Original Medications and Generics
Branded Proprietary IOP-lowering Medications
Generic IOP-lowering Medications
Branded Generics

FORECAST FOR THE GLAUCOMA PHARMA MARKET

Prospects in Wealthy Nations
Economic Shifts in Emerging Markets
Changing Role of Glaucoma Procedures
Global Market for Glaucoma Medications
The Global Market by Medication Class
The Global Market by Competitor
Forecast for the Global Glaucoma Rx Market
US Market for Glaucoma Medications
Western Europe's Market for Glaucoma Medications
Japan's Market for Glaucoma Medications
OWN's Market for Glaucoma Medications
China's Market for Glaucoma Medications
India's Market for Glaucoma Medications
Latin America's Market for Glaucoma Medications
ROW's Market for Glaucoma Medications

DEVELOPMENT PIPELINE FOR GLAUCOMA PHARMA

Prostaglandin Analogs
Bausch + Lomb/Nicox: Vyzulta
Nicox: NCX 470
Ono Pharmaceutical/Santen Sepetaprost
Santen/Novagali Pharma: Catioprost
Rho-kinase Inhibition
Aerie Pharmaceuticals: Rhopressa
pH Pharma PHP-201
Discontinued Rho-Kinase Inhibitors
Adenosine Receptor Agonists and Antagonists
Inotek Pharmaceuticals: Trabodendoson
Acorn Biomedical: ACN-1052
Discontinued Adenosine Receptor Agonists
EP Receptor Agonists
Santen: DE-117 (omidenepeg isopropyl)
Discontinued EP Receptor Agonists
Additional IOP-lowering Compounds
Sylentis: Bamosiran (SYL-040012)
Neuroprotection and Neuroregeneration
Quark Pharmaceuticals: QPI-1007
Merz Pharmaceuticals: MRZ-99030

Other Neuroprotective Compounds
Discontinued Candidates
Fixed Combinations of Agents
Aerie Pharmaceuticals: Roclatan
Inotek: Trabodendoson Plus Latanoprost
Laboratoires Théa: T2347
New Drug Delivery Technologies
Clinical Stage Programs
Preclinical Programs
Review of Investigational Technologies

ADJUNCTIVE DRUGS USED IN GLAUCOMA SURGERY

Compounds Used Off Label
Möbius Therapeutics' Mitosol
Altacor/Esperante's ALT 401 (Tranilast)

COMPANY PROFILES

Aerie Pharmaceuticals
Akorn
Allergan, PLC
Amorphex Therapeutics LLC
Bausch + Lomb
Envisia Therapeutics
Inotek Pharmaceuticals Corporation
Laboratoires Théa
Laboratorios Sophia, SA de CV
Mati Therapeutics, Inc.
Merz GmbH & Co. KGaA
Möbius Therapeutics LLC
Neurotech Pharmaceuticals, Inc.
Nicox
Novartis
Ocular Therapeutix
Ono Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Pfizer
pH Pharma
Quark Pharmaceuticals
Santen Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries, Inc.
Sylentis
Teva
ViSci Ltd.

Market Scope

9859 Big Bend Blvd, Suite 202
St. Louis, MO 63122
market-scope.com